A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

February 5, 2025

Study Completion Date

February 5, 2025

Conditions

Healthy

Interventions

DRUG

Orforglipron

Administered orally

DRUG

Midazolam

Administered orally

DRUG

Quinidine

Administered orally

Trial Locations (1)

ICON, Salt Lake City

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06704763 - A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants | Biotech Hunter | Biotech Hunter